Minor contribution of biliary excretion in lithium elimination in rats
-
Yuichi Uwai
,
Tatsuya Kawasaki
Abstract
Background: Lithium, which is often used for the treatment of bipolar disorders, is mainly recovered into urine after being orally administered. Due to the fact that it is completely absorbed via the gastrointestinal tract, it remains unknown whether biliary excretion is involved in the lithium disposition. In this study, we examined biliary excretion of lithium in rats and compared these with renal excretion.
Materials and methods: After the injection of lithium chloride to femoral vein, plasma levels and excretion into urine and bile of lithium were evaluated.
Results: After its intravenous administration as a bolus, the plasma concentration of lithium decreased time-dependently. Until 60 min, 6.47% and 0.694% of injected lithium were excreted into urine and bile, respectively. The biliary clearance of lithium was calculated to be 0.0779 mL/min/kg, and this was 11.3% of the renal clearance.
Conclusions: These findings suggest the low ability of the liver to eliminate lithium from plasma in comparison with the kidney in rats.
Acknowledgments
This work was supported by Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (Grant No. 26860117).
Author contributions: All the authors accept responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Conflict of interest: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Finley PR, Warner MD, Peabody CA. Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995; 29:172–91.10.2165/00003088-199529030-00004Search in Google Scholar PubMed
2. Price LH, Heninger GR. Lithium in the treatment of mood disorders. N Engl J Med 1994;331:591–8.10.1056/NEJM199409013310907Search in Google Scholar PubMed
3. Thornhill DP. The biological disposition and kinetics of lithium. Biopharm Drug Dispos 1981;2:305–22.10.1002/bdd.2510020403Search in Google Scholar PubMed
4. Thomsen K, Schou M. Renal lithium excretion in man. Am J Physiol 1968;215:823–7.10.1152/ajplegacy.1968.215.4.823Search in Google Scholar PubMed
5. Koomans HA, Boer WH, Dorhout Mees EJ. Evaluation of lithium clearance as a marker of proximal tubule sodium handling. Kidney Int 1989;36:2–12.10.1038/ki.1989.153Search in Google Scholar PubMed
6. Uwai Y, Arima R, Takatsu C, Furuta R, Kawasaki T, Nabekura T. Sodium-phosphate cotransporter mediates reabsorption of lithium in rat kidney. Pharmacol Res 2014;87:94–8.10.1016/j.phrs.2014.06.012Search in Google Scholar PubMed
7. Shirley DG, Walter SJ, Sampson B. A micropuncture study of renal lithium reabsorption: effects of amiloride and furosemide. Am J Physiol 1992;263:F1128–33.10.1152/ajprenal.1992.263.6.F1128Search in Google Scholar PubMed
8. Fransen R, Boer WH, Boer P, Dorhout Mees EJ, Koomans HA. Effects of furosemide or acetazolamide infusion on renal handling of lithium: a micropuncture study in rats. Am J Physiol 1993;264:R129–34.10.1152/ajpregu.1993.264.1.R129Search in Google Scholar PubMed
©2015 by De Gruyter
Articles in the same Issue
- Frontmatter
- Editorial
- From DMDI “Drug Metabolism and Drug Interactions” to DMPT “Drug Metabolism and Personalized Therapy”
- Review
- Clinical drug-drug interactions: focus on venlafaxine
- Reviews in Population Pharmacogenomics
- Pharmacogenetics in Central American healthy volunteers: interethnic variability
- Genomic biomarkers related to drug response in Venezuelan populations
- Originial Articles
- No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia
- Chloral hydrate, through biotransformation to dichloroacetate, inhibits maleylacetoacetate isomerase and tyrosine catabolism in humans
- Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects
- Minor contribution of biliary excretion in lithium elimination in rats
- Case Report
- Fatal hyperkalemia following succinylcholine administration in a child on oral propranolol
Articles in the same Issue
- Frontmatter
- Editorial
- From DMDI “Drug Metabolism and Drug Interactions” to DMPT “Drug Metabolism and Personalized Therapy”
- Review
- Clinical drug-drug interactions: focus on venlafaxine
- Reviews in Population Pharmacogenomics
- Pharmacogenetics in Central American healthy volunteers: interethnic variability
- Genomic biomarkers related to drug response in Venezuelan populations
- Originial Articles
- No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia
- Chloral hydrate, through biotransformation to dichloroacetate, inhibits maleylacetoacetate isomerase and tyrosine catabolism in humans
- Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects
- Minor contribution of biliary excretion in lithium elimination in rats
- Case Report
- Fatal hyperkalemia following succinylcholine administration in a child on oral propranolol
